Predictive 5-year survivorship model of cystic fibrosis
- PMID: 11207152
- PMCID: PMC2198936
- DOI: 10.1093/aje/153.4.345
Predictive 5-year survivorship model of cystic fibrosis
Abstract
The objective of this study was to create a 5-year survivorship model to identify key clinical features of cystic fibrosis. Such a model could help researchers and clinicians to evaluate therapies, improve the design of prospective studies, monitor practice patterns, counsel individual patients, and determine the best candidates for lung transplantation. The authors used information from the Cystic Fibrosis Foundation Patient Registry (CFFPR), which has collected longitudinal data on approximately 90% of cystic fibrosis patients diagnosed in the United States since 1986. They developed multivariate logistic regression models by using data on 5,820 patients randomly selected from 11,630 in the CFFPR in 1993. Models were tested for goodness of fit and were validated for the remaining 5,810 patients for 1993. The validated 5-year survivorship model included age, forced expiratory volume in 1 second as a percentage of predicted normal, gender, weight-for-age z score, pancreatic sufficiency, diabetes mellitus, Staphylococcus aureus infection, Burkerholderia cepacia infection, and annual number of acute pulmonary exacerbations. The model provides insights into the complex nature of cystic fibrosis and supplies a rigorous tool for clinical practice and research.
Figures
Similar articles
-
Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study.Lancet Respir Med. 2016 Aug;4(8):636-645. doi: 10.1016/S2213-2600(16)30105-9. Epub 2016 Jun 10. Lancet Respir Med. 2016. PMID: 27298019 Free PMC article.
-
Clinical and demographic factors associated with post-lung transplantation survival in individuals with cystic fibrosis.J Heart Lung Transplant. 2015 Sep;34(9):1139-45. doi: 10.1016/j.healun.2015.05.003. Epub 2015 May 7. J Heart Lung Transplant. 2015. PMID: 26087666
-
[Italian Cystic Fibrosis Registry. Report 2011-2014].Epidemiol Prev. 2018 Jan-Feb;42(1S1):1-32. doi: 10.19191/EP18.1-S1.P001.001. Epidemiol Prev. 2018. PMID: 29506377 Italian.
-
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.Cochrane Database Syst Rev. 2015 Mar 26;(3):CD009841. doi: 10.1002/14651858.CD009841.pub2. Cochrane Database Syst Rev. 2015. PMID: 25811419 Updated. Review.
-
Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.Cochrane Database Syst Rev. 2006 Jul 19;(3):CD002009. doi: 10.1002/14651858.CD002009.pub2. Cochrane Database Syst Rev. 2006. PMID: 16855982 Updated. Review.
Cited by
-
Airway inflammation accelerates pulmonary exacerbations in cystic fibrosis.iScience. 2024 Jan 9;27(3):108835. doi: 10.1016/j.isci.2024.108835. eCollection 2024 Mar 15. iScience. 2024. PMID: 38384849 Free PMC article.
-
Integrating airway microbiome and blood proteomics data to identify multi-omic networks associated with response to pulmonary infection.Microbe. 2023 Dec;1:100023. doi: 10.1016/j.microb.2023.100023. Epub 2023 Nov 28. Microbe. 2023. PMID: 38264413 Free PMC article.
-
Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis.Front Pharmacol. 2023 Dec 14;14:1275470. doi: 10.3389/fphar.2023.1275470. eCollection 2023. Front Pharmacol. 2023. PMID: 38186649 Free PMC article.
-
P. aeruginosa interactions with other microbes in biofilms during co-infection.AIMS Microbiol. 2023 Aug 10;9(4):612-646. doi: 10.3934/microbiol.2023032. eCollection 2023. AIMS Microbiol. 2023. PMID: 38173971 Free PMC article. Review.
-
Improved recognition of lung function decline as signal of cystic fibrosis pulmonary exacerbation: a Cystic Fibrosis Learning Network Innovation Laboratory quality improvement initiative.BMJ Open Qual. 2023 Dec 28;12(4):e002466. doi: 10.1136/bmjoq-2023-002466. BMJ Open Qual. 2023. PMID: 38154821 Free PMC article.
References
-
- Anderson DH. Cystic fibrosis of the pancreas and its relation to celiac disease. A clinical and pathologic study. Am J Dis Child. 1938;56:344–95.
-
- Farber S. Some organic digestive disturbances in early life. J Michigan Med Sci. 1945;44:587–94.
-
- Cystic Fibrosis Foundation Patient Registry annual data report, 1998. Bethesda, MD; Cystic Fibrosis Foundation: 1999.
-
- Isles A, Maclusky I, Corey M, et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr. 1984;104:206–10. - PubMed
-
- Thomassen MJ, Demko CA, Klinger JD, et al. Pseudomonas cepacia colonization among patients with cystic fibrosis. Am Rev Respir Dis. 1985;131:791–6. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
